Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0015 | 0.0458 | 0.5 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0015 | 0.0458 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.1652 | 0.1652 |
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 0.9427 | 0.9427 |
Loa Loa (eye worm) | AStacin protease | 0.0029 | 0.4721 | 0.4721 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.0047 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0458 | 0.0458 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0047 | 1 | 1 |
Brugia malayi | Fibulin-1 precursor | 0.0015 | 0.0458 | 1 |
Echinococcus multilocularis | Tolloid protein 1 | 0.0047 | 1 | 1 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0015 | 0.0458 | 0.0458 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0015 | 0.0458 | 0.5 |
Onchocerca volvulus | Arrow homolog | 0.0014 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.